Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors

Immunologic Research

Volumn 42, Issue 1-3, 2008, Pages 233-245

  Wood, Laurence M ^a   Guirnalda, Patrick D ^a   Seavey, Matthew M ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antigen processing; Cell mediated immunity; Her 2 neu; HPV; Listeria monocytogenes; Tumor immunotherapy; Tumor vasculature; Vaccines

Indexed keywords

BACTERIAL VECTOR; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOLECULAR WEIGHT MELANOMA ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; LISTERIOLYSIN O; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOPROTEIN; PROTEIN E6; PROTEIN E7; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL TOXIN; HEAT SHOCK PROTEIN; HEMOLYSIN; HLYA PROTEIN, LISTERIA MONOCYTOGENES;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; B CELL LYMPHOMA; BACTERIAL GROWTH; BREAST CANCER; BREAST TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LUNG CARCINOMA; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR; TUMOR REGRESSION; UTERINE CERVIX CANCER; ANIMAL; ARTICLE; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

ANIMALS; BACTERIAL TOXINS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; HUMANS; IMMUNOTHERAPY; LISTERIA MONOCYTOGENES; LYMPHOMA, NON-HODGKIN; VIRULENCE FACTORS;

EID: 61849090915     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-008-8087-0     Document Type: Review

References (55)

1. Sabin A. Presidential Address to the Infectious Disease Society of America. 1983.
2. Paterson Y. Rational approaches to immune regulation. Immunol Res. 2003;27:451-62. (Cancro M, Monroe J, editors).
3. Paterson Y. The relationship between bacterial life-styles and the immune responsiveness to bacterially delivered antigens. In: Paterson Y, editor. Intracellular bacteria as live recombinant vaccine vectors Immunology cell biology and genetics. New York, NY: Wiley; 1999. p. 1-24.
4. LG Tilney DA Portnoy 1989 Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes J Cell Biol 109 1597 1608 2507553 10.1083/jcb.109.4.1597 1:CAS:528:DyaL1MXmtFWrsbk%3D
5. DA Portnoy RD Schreiber P Connelly LG Tilney 1989 Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm J Exp Med 170 2141 6 2511268 10.1084/jem.170.6.2141 1:CAS:528:DyaK3cXnsFShtQ%3D%3D (Pubitemid 20010091)
6. SHE Kaufmann 1993 Immunity to intracellular bacteria Annu Rev Immunol 11 129 63 8476559 10.1146/annurev.iy.11.040193.001021 1:CAS:528:DyaK3sXktVKmu70%3D
7. + Listeria immune T cells Immunology 60 287 93 3493210 1:CAS:528:DyaL2sXhtlKmsbk%3D
8. + cells in acquired immunity Infect Immun 56 1920 5 2969373 1:STN:280:BieB1cvptFU%3D
9. + T cells requires secretion of hemolysin and intracellular bacterial growth J Immunol 145 3540 6 2147195 1:CAS:528:DyaK3MXit1eguw%3D%3D
10. P Berche J Gaillard PJ Sansonetti 1987 Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity J Immunol 138 2266 71 3104455 1:STN:280:BiiC28jlsl0%3D
11. Weiskirch L, Paterson Y. The use of Listeria monocytogenes recombinants as vaccine vectors in infectious and neoplastic disease. In: Paterson Y, editor. Chapter 7 in Intracellular bacteria as live recombinant vaccine vectors: Immunology, cell biology and genetics. New York, NY: Wiley; 1999. p. 223-59.
12. Vijh S, Pamer EG. The cell biology and immune response to Listeria monocytogenes, an intracellular pathogen. In: Paterson Y, editor. Chapter 3 in Intracellular bacteria as live recombinant vaccine vectors: Immunology, cell biology and genetics. New York, NY: Wiley; 1999.
13. OJ Finn 2008 Cancer immunology N Engl J Med 358 2704 15 18565863 10.1056/NEJMra072739 1:CAS:528:DC%2BD1cXns1ajt7k%3D (Pubitemid 351860863)
14. LA Jones ML Salgaller 2000 Immunologic approaches to antigen discovery for cancer vaccines Expert Opin Investig Drugs 9 481 90 11060689 10.1517/13543784.9.3.481 1:CAS:528:DC%2BD3cXhslKnsLs%3D
15. DM Pardoll 1999 Inducing autoimmune disease to treat cancer Proc Natl Acad Sci USA 96 5340 2 10318881 10.1073/pnas.96.10.5340 1:CAS:528: DyaK1MXjtFCnsro%3D (Pubitemid 29234615)
16. Z-K Pan G Ikonomidis A Lazenby D Pardoll Y Paterson 1995 A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour challenge and causes regression of established tumours Nat Med 1 471 7 7585097 10.1038/nm0595-471 1:CAS:528:DyaK2MXls1SgtLk%3D
17. Z-K Pan G Ikonomidis D Pardoll Y Paterson 1995 Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine Cancer Res 55 4776 9 7585503 1:CAS:528:DyaK2MXptFKitb0%3D
18. Z-K Pan LM Weiskirch Y Paterson 1999 Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine Cancer Res 59 5264 9 10537307 1:CAS:528:DyaK1MXmvFelsbw%3D
19. LM Weiskirch Z-K Pan Y Paterson 2001 The tumor recall response of anti-tumor immunity primed by a live, recombinant L. monocytogenes vaccine is comprised of multiple effector mechanisms Clin Immunol 98 346 57 11237558 10.1006/clim.2000.4987 1:CAS:528:DC%2BD3MXislahtLs%3D (Pubitemid 32205299)
20. G Ikonomidis Y Paterson F Kos D Portnoy 1994 Delivery of a viral antigen to the class I processing and presentation pathway by L. monocytogenes J Exp Med 180 2209 18 7964496 10.1084/jem.180.6.2209 1:CAS:528:DyaK2cXmsFehtb4%3D (Pubitemid 24351602)
21. EM Jaffee DM Pardoll 1997 Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines Methods 12 143 53 9184378 10.1006/meth.1997.0463 1:CAS:528:DyaK2sXjtlSksr4%3D (Pubitemid 27241370)
22. SJ Antonia 1999 B7-1 gene-modified tumor cell vaccines Curr Opin Mol Ther 1 50 6 11249684 1:CAS:528:DyaK1MXhvVOrtL4%3D
23. ME Dominiecki GL Beatty Z-K Pan P Neeson Y Paterson 2005 Tumor sensitivity to IFNγ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors Cancer Immunol Immunother 54 477 88 15750832 10.1007/s00262-004-0610-0 1:CAS:528:DC%2BD2MXhvFyrsL8%3D (Pubitemid 40543687)
24. RW Tindle 1996 Human papilloma virus vaccines for cervical cancer Curr Opin Immunol 8 643 50 8902389 10.1016/S0952-7915(96)80080-X 1:CAS:528: DyaK28Xmt1Ogtrs%3D (Pubitemid 26385392)
25. KY Lin FG Guarnieri KF Staveley-O'Carroll HI Levitsky JT August DM Pardoll TC Wu 1996 Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen Cancer Res 56 21 6 8548765 1:CAS:528:DyaK28Xit1CjtA%3D%3D
26. GR Gunn A Zubair CH Peters Z-K Pan T-C Wu Y Paterson 2001 Two L. monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16 J Immunol 167 6471 9 11714814 1:CAS:528:DC%2BD3MXovVCit7c%3D
27. GR Gunn C Peters Y Paterson 2001 Listeriolysin - a useful cytolysin Trends in Microbiol 9 161 2 10.1016/S0966-842X(01)02006-6 1:CAS:528: DC%2BD3MXlvFSgurc%3D
28. DA Sewell V Shahabi GR Gunn III Z-K Pan ME Dominiecki Y Paterson 2004 Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor associated antigen human papillomavirus-16 E7 Cancer Res 64 8821 5 15604239 10.1158/0008-5472.CAN-04-1958 1:CAS:528:DC%2BD2cXhtVOmsL7M (Pubitemid 39665484)
29. + T cell responses that home to the tumor site J Virol 75 9654 64 11559797 10.1128/JVI.75.20.9654-9664.2001 1:CAS:528:DC%2BD3MXnt1Ghtbg%3D (Pubitemid 32900100)
30. DA Sewell D Douven Z-K Pan A Rodriguez Y Paterson 2004 Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine Arch Otolaryngol Head Neck Surg 130 92 7 14732776 10.1001/archotol.130.1.92 (Pubitemid 38095437)
31. X Peng J Treml Y Paterson 2007 Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy Cancer Immunol Immunother 56 797 806 17102978 10.1007/s00262-006-0240-9 1:CAS:528:DC%2BD2sXjsFyhtbo%3D (Pubitemid 46723587)
32. S Noor H Goldfine DE Tucker S Suram LL Lenz S Akira S Uematsu M Girotti JV Bonventre K Breuel DL Williams CC Leslie 2008 Activation of cytosolic phospholipase A2alpha in resident peritoneal macrophages by Listeria monocytogenes involves listeriolysin O and TLR2 J Biol Chem 283 4744 55 18083708 10.1074/jbc.M709956200 1:CAS:528:DC%2BD1cXhvFeksrw%3D
33. T Nishibori H Xiong I Kawamura M Arakawa M Mitsuyama 1996 Induction of cytokine gene expression by listeriolysin O and roles of macrophages and NK cells Infect Immun 64 3188 95 8757852 1:CAS:528:DyaK28XksFGitbg%3D
34. C Kohda I Kawamura H Baba, et al. 2002 Dissociated linkage of cytokine-inducing activity and cytotoxicity to different domains of listeriolysin O from Listeria monocytogenes Infect Immun 70 1334 41 11854218 10.1128/IAI.70.3.1334-1341.2002 1:CAS:528:DC%2BD38XhsFSlsLo%3D (Pubitemid 34163409)
35. P Neeson ZK Pan Y Paterson 2008 Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma Cancer Immunol Immunother 57 493 505 17876582 10.1007/s00262-007-0388-y 1:CAS:528:DC%2BD1cXhtV2ju7c%3D (Pubitemid 351170533)
36. RE Hawkins D Zhu M Ovecka G Winter TJ Hamblin A Long FK Stevenson 1994 Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines Blood 83 3279 88 8193363 1:CAS:528:DyaK2MXhsFGntA%3D%3D
37. Y Bergman J Haimovich 1977 Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin Eur J Immunol 7 413 17 408154 10.1002/eji.1830070702 1:CAS:528:DyaE2sXltlaisr8%3D
38. MS Kaminski K Kitamura DG Maloney R Levy 1987 Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein J Immunol 138 1289 96 3492546 1:CAS:528:DyaL2sXhtlKmsbg%3D
39. + immunoregulatory cells J Immunol 167 1137 40 11466326 1:CAS:528:DC%2BD3MXls1WktL0%3D
40. + immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25 202 6 10.1097/00002371-200205000-00002 (Pubitemid 34533309)
41. + Regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector J Immunother 27 5 339 46 15314542 10.1097/00002371-200409000-00002 1:CAS:528:DC%2BD2cXmsl2hu7s%3D
42. J Nitcheu-Tefit M-S Dai RJ Critchley-Thorne F Ramirez-Jimenez M Xu S Conchon N Ferry HJ Stauss G Vassaux 2007 Listeriolysin O expressed in a bacterial vaccine suppresses CD4+ CD25 high regulatory T cell function in vivo J Immunol 179 1532 41 17641019 1:CAS:528:DC%2BD2sXnvVynt7g%3D
43. NC Souders DA Sewell Z-K Pan SF Hussain A Rodriguez A Wallecha Y Paterson 2007 Listeria based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer Cancer Immun 7 1 12
44. H Bernhard L Salazar K Schiffman A Smorlesi B Schmidt KL Knutson ML Disis 2002 Vaccination against the HER-2/neu oncogenic protein Endocr Relat Cancer 9 33 44 11914181 10.1677/erc.0.0090033 1:CAS:528:DC%2BD38XjsVCltLc%3D (Pubitemid 34298362)
45. AM Ercolini, et al. 2003 Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice J Immunol 170 4273 80 12682262 1:CAS:528:DC%2BD3sXislers7c%3D
46. WJ Muller 1991 Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer Cancer Metastasis Rev 10 217 27 1662559 10.1007/BF00050793 1:STN:280:By2C3M%2FovFU%3D
47. CT Guy, et al. 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci USA 89 10578 82 1359541 10.1073/pnas.89.22.10578 1:CAS:528:DyaK3sXjs1ymsw%3D%3D
48. R Singh 2005 Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse J Immunol 175 3663 73 16148111 1:CAS:528: DC%2BD2MXpslClsr4%3D
49. R Singh Y Paterson 2007 Immunoediting sculpts tumor epitopes during immunotherapy Cancer Res 67 1887 92 17332314 10.1158/0008-5472.CAN-06-3960 1:CAS:528:DC%2BD2sXit12qtbs%3D (Pubitemid 46424202)
50. R Singh Y Paterson 2006 Vaccination strategy determines the emergence and dominance of CD8 + T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer Cancer Res 66 7748 57 16885378 10.1158/0008-5472.CAN-05-4469 1:CAS:528:DC%2BD28XnsFyqsrg%3D (Pubitemid 44289235)
51. R Singh Y Paterson 2007 In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines Cancer Immunol Immunother 56 927 38 17131121 10.1007/s00262-006-0237-4 1:CAS:528:DC%2BD2sXjsFyhtbc%3D (Pubitemid 46723584)
52. MR Campoli CC Chang T Kageshita X Wang JB McCarthy S Ferrone 2004 Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance Crit Rev Immunol 24 267 96 15588226 10.1615/CritRevImmunol.v24.i4. 40 1:CAS:528:DC%2BD2MXotFOksw%3D%3D (Pubitemid 40052428)
53. P Baluk H Hashizume DM McDonald 2005 Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 102 11 15661540 10.1016/j.gde.2004.12.005 1:CAS:528:DC%2BD2MXmvFertQ%3D%3D (Pubitemid 40127638)
54. D Von Tell A Armulik C Betsholtz 2006 Pericytes and vascular stability Exp Cell Res 312 5 623 9 10.1016/j.yexcr.2005.10.019 (Pubitemid 43290338)
55. P Maciag M Seavey Z Pan S Ferrone Y Paterson 2008 Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature Cancer Res. 68 8066 75 18829565 10.1158/0008-5472.CAN-08-0287 1:CAS:528:DC%2BD1cXhtF2msLvN